This site is intended for US healthcare professionals only

Mechanism of Action

Optune Lua® uses electrical fields to disrupt cancer cell viability.1

In MPM, only Optune Lua delivers TTFields, which exert antitumor effects by disrupting the activity of cancer cells during multiple phases of mitosis (cell division)1,2,4

TTFields are alternating electric fields delivered at a unique frequency that allows them to selectively disrupt MPM cancer cell division1

Healthy cells have different properties (including division rate, morphology, and electrical properties), than cancer cells, and therefore are not significantly affected by Optune Lua treatment7-12

View TTFields mechanism of action video

This video showcases the detailed process of how TTFields disrupt cancer cell division.

Optune Lua is FDA approaved as first-line therapy together with pemetrexed and platinum-based chemotherapy for patients with MPM1,13

See overall survival results

MPM, malignant pleural mesothelioma; TTFields, Tumor Treating Fields

 

References: 1. Optune Lua. Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2021. 2. Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015;5:1-16. doi:10.1038/srep18046 3. Kirson ED, Dbalý V, Tovaryš F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA. 2007; 104(24):10152-10157. doi:10.1073/pnas.0702916104 4. Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64(9):3288-95. doi:10.1158/0008-5472.can-04-0083 5. Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One. 2015;10(5):1-20. doi:10.1371/journal.pone.0125269 6. Voloshin T, Kaynan N, Davidi S, et al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother. 2020;69(7):1191-1204. doi:10.1007/s00262-020-02534-7 7. Karanam NK, Story MD. An overview of potential novel mechanisms of action underlying tumor treating fields-induced cancer cell death and their clinical implications. Int J Radiat Biol. 2021;97(8):1044-1054. doi:10.1080/09553002.2020.1837984 8. Cooper GM. The development and causes of cancer. In: The Cell: A Molecular Approach. 2nd ed. Sinauer Associates; 2000:chap 15. Accessed July 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK9963/ 9. Baba AI, Câtoi C. Tumor cell morphology. In: Comparative Oncology. The Publishing House of the Romanian Academy; 2007:chap 3. Accessed July 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK9553/ 10. Trainito CI, Sweeney DC, Čemažar J, et al. Characterization of sequentially-staged cancer cells using electrorotation. PLoS One. 2019;14(9):1-18. doi:10.1371/journal.pone.0222289 11. Haemmerich D, Schutt DJ, Wright AW, Webster JG, Mahvi DM. Electrical conductivity measurement of excised human metastatic liver tumours before and after thermal ablation. Physiol Meas. 2009;30(5):459-466. doi:10.1088/0967-3334/30/5/003 12. Ahmad MA, (IEEE SM), Al Natour Z, Mustafa F, Rizvi TA. Electrical characterization of normal and cancer cells. IEEE Access. 2018;6:25979-25986. doi:10.1109/ACCESS.2018.2830883 13. FDA Approves the NovoTTF- 100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [press release]. St. Helier, Jersey: Business Wire; May 23, 2019.

Caution: Federal law restricts this device to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal Law for use in the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma concurrently with pemetrexed and platinum-based chemotherapy. The effectiveness of this device for this use has not been demonstrated.

 

Indication For Use

Optune Lua® is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used concurrently with pemetrexed and platinum-based chemotherapy.

 

Important Safety Information 

Contraindications

Do not use Optune Lua in patients with implantable electronic medical devices such as pacemakers or implantable automatic defibrillators, etc. Use of Optune Lua together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device.

 

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. Skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and may rarely lead to severe allergic reactions such as shock and respiratory failure.

 

Warnings and Precautions

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®.

 

The most common (≥10%) adverse events involving Optune Lua in combination with chemotherapy were anemia, constipation, nausea, asthenia, chest pain, fatigue, medical device site reaction, pruritus, and cough.

 

Other potential adverse effects associated with the use of Optune Lua include: treatment related skin toxicity, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical device site reaction and skin breakdown/skin ulcer.

 

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

 

Do not prescribe Optune Lua for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established.

 

Please click here to see Optune Lua Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

Novocure Websites

This website is intended for people seeking information on Optune Lua.

 

On this site, videos and images identified as Optune Lua users, care partners, or healthcare professionals depict actual patients, care partners, and healthcare professionals.

 

Patient images reflect the health status of the patients at the time each photo or video was taken.


External links

Tumortreatingfieldstherapy.com
Optunegio.com
Optunelua.com
Novocure.com
Novocuretrials.com


©2024 Novocure GmbH. All Rights Reserved.

MyNovocure, Novocure, and Optune Lua are registered trademarks of Novocure GmbH.

US-OPL-00020 v1.0 August 2024